Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
Dai WF, Craig E, Fraser B, Chambers A, Mai H, Brown MB, Earle CC, Evans WK, Geirnaert M, Taylor M, Trudeau M, Sperber D, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration. Dai WF, et al. Curr Oncol. 2021 Nov 12;28(6):4645-4654. doi: 10.3390/curroncol28060392. Curr Oncol. 2021. PMID: 34898572 Free PMC article.
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Chan KKW, Guo H, Cheng S, Beca JM, Redmond-Misner R, Isaranuwatchai W, Qiao L, Earle C, Berry SR, Biagi JJ, Welch S, Meyers BM, Mittmann N, Coburn N, Arias J, Schwartz D, Dai WF, Gavura S, McLeod R, Kennedy ED. Chan KKW, et al. Among authors: dai wf. Cancer Med. 2020 Jan;9(1):160-169. doi: 10.1002/cam4.2705. Epub 2019 Nov 13. Cancer Med. 2020. PMID: 31724340 Free PMC article.
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
Phillips CM, Parmar A, Guo H, Schwartz D, Isaranuwatchai W, Beca J, Dai W, Arias J, Gavura S, Chan KKW. Phillips CM, et al. Cancer. 2020 Apr 15;126(8):1717-1726. doi: 10.1002/cncr.32697. Epub 2020 Jan 8. Cancer. 2020. PMID: 31913522 Free article.
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K, Nam S, Evans B, de Oliveira C, Chambers A, Gavura S, Hoch J, Mercer RE, Dai WF, Beca J, Tadrous M, Isaranuwatchai W. Chan K, et al. Among authors: dai wf. BMJ Open. 2020 Jan 7;10(1):e032884. doi: 10.1136/bmjopen-2019-032884. BMJ Open. 2020. PMID: 31915169 Free PMC article.
Impact of rarity on Canadian oncology health technology assessment and funding.
Keech J, Dai WF, Trudeau M, Mercer RE, Naipaul R, Wright FC, Ferguson SE, Darling G, Gavura S, Eisen A, Kouroukis CT, Beca J, Chan KKW. Keech J, et al. Among authors: dai wf. Int J Technol Assess Health Care. 2020 Aug 11:1-6. doi: 10.1017/S0266462320000483. Online ahead of print. Int J Technol Assess Health Care. 2020. PMID: 32779560
50 results